FORMYCON AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.95 EUR | -1.56% |
|
+7.20% | -27.39% |
| 25/04 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 18/03 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
Evolution of the average Target Price on Formycon AG
Price target over the last 5 years
History of analyst recommendation changes
80ce768e69f9f20f.Tyoy1BI_FciTOV-_HRu-AWhkQu1tTfhtRVSADleG2pM.AGtKn2B0Y-WrdRbIV2zdRwwSKtspHrsAEGPXZjn2m8MoclWDRGpaq8Z2Bg~23c3b9dd6968c2a6339d1a2f8d24bb1a
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
40.95
EUR
Average target price
91.8
EUR
Spread / Average Target
+124.18%
High Price Target
101
EUR
Spread / Highest target
+146.64%
Low Price Target
81
EUR
Spread / Lowest Target
+97.80%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
- Stock Market
- Equities
- FYB Stock
- Consensus Formycon AG
